Protective Efficacy of a Toxoplasma gondii Rhoptry Protein 13 Plasmid DNA Vaccine in Mice
Protective Efficacy of a Toxoplasma gondii Rhoptry Protein 13 Plasmid DNA Vaccine in Mice
复制标题
DOI：
10.1128/cvi.00397-12
复制
发表时间：
2012-12-01
影响因子：
--
通讯作者：
Zhu, Xing-Quan
中科院分区：
文献类型：
--
作者：
Wang, Pei-Yuan;Yuan, Zi-Guo;Zhu, Xing-Quan
弓形虫是一种专性细胞内寄生虫，感染人类和其他温血动物，在世界范围内造成严重的公共卫生问题和经济损失。棒状体参与了T.弓形虫入侵和宿主细胞相互作用，并已被认为是重要的毒力因子。本研究以表达T.构建了弓形虫真核表达载体pVAX I，并对其诱导的免疫保护作用进行了评价。用pVAX-ROP 13和/或白细胞介素18（IL-18）肌肉注射免疫昆明小鼠。然后，我们用淋巴细胞增殖试验、细胞因子和抗体测定以及用强毒T.弓形虫RH株（I型）和形成包囊的PRU株（II型）。结果表明，pVAX-ROP 13单独或与pVAX/IL-18联合诱导产生高水平的特异性抗T细胞抗体。弓形虫抗体和特异性淋巴细胞增殖反应。共注射pVAX/IL-18显著增加γ干扰素（IFN-γ）、IL-2、IL-4和IL-10的产生。此外，攻击实验显示，与单独的pVAX-ROP 13（24.9 +/-2.3天）相比，pVAX-ROP 13与pVAX/IL-18的共免疫显著（P < 0.05）增加了存活时间（32.3 +/-2.7天）。用T.弓形虫包囊（PRU株）的脑包囊数量显著减少，表明ROP 13可以引发针对弓形虫包囊的强烈体液和细胞应答。结论弓形虫病疫苗是一种潜在的弓形虫病疫苗候选物，为进一步研制弓形虫病疫苗奠定了基础。刚地。
Toxoplasma gondii is an obligate intracellular parasite infecting humans and other warm-blooded animals, resulting in serious public health problems and economic losses worldwide. Rhoptries are involved in T. gondii invasion and host cell interaction and have been implicated as important virulence factors. In the present study, a DNA vaccine expressing rhoptry protein 13 (ROP13) of T. gondii inserted into eukaryotic expression vector pVAX I was constructed, and the immune protection it induced in Kunming mice was evaluated. Kunming mice were immunized intramuscularly with pVAX-ROP13 and/or with interleukin-18 (IL-18). Then, we evaluated the immune response using a lymphoproliferative assay, cytokine and antibody measurements, and the survival times of mice challenged with the virulent T. gondii RH strain (type I) and the cyst-forming PRU strain (type II). The results showed that pVAX-ROP13 alone or with pVAX/IL-18 induced a high level of specific anti-T. gondii antibodies and specific lymphocyte proliferative responses. Coinjection of pVAX/IL-18 significantly increased the production of gamma interferon (IFN-gamma), IL-2, IL-4, and IL-10. Further, challenge experiments showed that coimmunization of pVAX-ROP13 with pVAX/IL-18 significantly (P < 0.05) increased survival time (32.3 +/- 2.7 days) compared with pVAX-ROP13 alone (24.9 +/- 2.3 days). Immunized mice challenged with T. gondii cysts (strain PRU) had a significant reduction in the number of brain cysts, suggesting that ROP13 could trigger a strong humoral and cellular response against T. gondii cyst infection and that it is a potential vaccine candidate against toxoplasmosis, which provided the foundation for further development of effective vaccines against T. gondii.